Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.43 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 10/20 | 0.41 |
| ▸ | ITGAV | P06756 | 10/20 | 0.41 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.38 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8682759 | 0.90 | ITGB3 (0.40) | ITGB3ITGAVITGB5ITGB1ITGB6 | |
| SCHEMBL7980652 | 0.79 | ITGB3 (0.61) | ITGB3ITGAVITGA2B | |
| SCHEMBL8683774 | 0.78 | SLC16A3 (0.41) | ITGB3ITGAVITGB5SLC22A12ITGB1 | |
| SCHEMBL7982200 | 0.78 | ITGAV (0.61) | ITGB3ITGAVITGB1ITGA2B | |
| SCHEMBL7979100 | 0.77 | ITGAV (0.68) | ITGB3ITGAVITGB1ITGA2B | |
| SCHEMBL8682718 | 0.75 | MAPK1 (0.44) | CSNK2A2CSNK2BCSNK2A1KDM4DITGB3 | |
| Trifluoroacetic Acid SCHEMBL7979079 | 0.74 | ITGAV (0.64) | ITGB3ITGAVITGB1ITGA2B | |
| SCHEMBL16607505 | 0.74 | ALDH1A1 (0.53) | KDM4DITGB3ITGAVITGB5HCAR3 | |
| SCHEMBL4261343 | 0.72 | SLC22A12 (0.60) | HCAR3PARP1SLC22A12 | |
| SCHEMBL6379876 | 0.71 | ITGB3 (0.65) | KDM4DITGB3ITGAVITGB5ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332149-B1 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-02-19 | — | — | US | disclosed |
| US-7321045-B2 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1140203-B1 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20050154185-A1 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2005-07-14 | — | — | US | disclosed |
| US-6838074-B2 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-04 | — | — | US | disclosed |
| US-20040208823-A1 | SIMULTANEOUS IMAGING OF CARDIAC PERFUSION AND A VITRONECTIN RECEPTOR TARGETED IMAGING AGENT | LANTHEUS MEDICAL IMAGING, INC. | 2004-10-21 | — | — | US | disclosed |
| US-6794518-B1 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-09-21 | — | — | US | disclosed |
| EP-1296678-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS FOR USE IN COMBINATION THERAPY | Bristol-Myers Squibb Pharma Company (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001098294-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS FOR USE IN COMBINATION THERAPY | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | disclosed |
| EP-1140203-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035488-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040208823-A1 | SIMULTANEOUS IMAGING OF CARDIAC PERFUSION AND A VITRONECTIN RECEPTOR TARGETED IMAGING AGENT | TNNI3, ASGR1, TNNT2 | CSNK2A2 4424/4885CSNK2B 4429/4885CSNK2A1 4502/4885 |
| US-20050154185-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | CSNK2A2 3894/4885CSNK2B 3166/4885CSNK2A1 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.